Filing Flows › Phathom Pharmaceuticals (PHAT) › Stock forecast & fair value
Phathom Pharmaceuticals (PHAT) stock forecast and price target
Phathom Pharmaceuticals (PHAT) trades at $5.25. 10 analysts' median price target is $21.50 (+310%), from $7.50 to $29.00.
Phathom Pharmaceuticals' latest quarter
Phathom Pharmaceuticals, Q3 2026: revenue $84.7M (+71% year over year), operating margin -0.1%, net loss $13.9M, operating cash flow $1.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for PHAT stock?
The median of 10 analysts' 12-month targets is $21.50, +310% from $5.25; the range is $7.50 to $29.00. The average rating is strong buy.
Does Phathom Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is PHAT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.